Enzymes tissue plasminogen activator

Tissue Plasminogen Aetivator (tPA). While streptokinase and urokinase can effectively induce clot dissolution in the majority of patients if given early, they lack clot specificity. Treatment with these enzymes results in a systemic lytic state attributable to their degradative action on circulating fibrinogen. Tissue plasminogen activator (tPA) was developed to achieve rapid and specific thrombolysis. 

Tissue plasminogen activator 530 amino acids, glycosylated E. coli Yeast Animal cells Acute mycocardial infarct Pulmonary embolism Approved for sale Animal cell culture most effective way of producing active enzyme... 

Plasminogen activator inhibitors have been shown to be present in a large variety of different cells and tissues. These inhibitors are thought to play an important role in regulating tissue fibrinolysis. One of these inhibitors has been purified from cultured bovine aortic epithelial cells. This inhibitor has been shown to be a serine protease inhibitor and inhibits the function of two proteolytic enzymes urokinase and tissue plasminogen activator, both of which cleave and activate plasminogen. The mechanism by which this inhibitor functions is very similar to that described above with a-l-PI. Thus, the inhibitor forms a binary complex with the proteolytic enzyme and thereby inhibits its activity. Again in a situation comparable to that with a-l-PI, it was found that when the purified bovine aortic epithelial inhibitor was exposed to Al-chlorosuccinimide,... 

Recent applications of HPAEC-PAD are many and varied. A representative list includes quantitation of polyglucose metabolites in plasma of dialysis patients,148 analysis of heat-treated milk,149 carbohydrate content in lipopolysaccharides,150 phosphorylated sugars in tissue samples,151 composition of soybean meal,152 carbohydrate composition of recombinant modified tissue plasminogen activator,153 analysis of cyclization products from an enzyme reaction,154 carbohydrate content of glycoconjugate vaccines,155 and monitoring of patients with rheumatoid arthritis.156... 

ACE-I, angiotensin-converting enzyme inhibitor ARB, angiotensin receptor blocker INR, International Normalized Ratio IV, intravenous t-PA, tissue plasminogen activator. 

The measurement of plasminogen activator inhibitor-1 (PAI-1), which complexes with tissue plasminogen activator (t-PA) and thus affects the ability of the latter to activate fibrinolysis, is useful in the assessment of fibrinolytic disorders (93). The complex formed by the fibrinolytic enzyme plasmin with its inhibitor... 

The role of the fibrinolytic system is to dissolve any clots that are formed within the intact vascular system and so restrict clot formation to the site of injury. The digestion of the fibrin and hence its lysis is catalysed by the proteolytic enzyme, plasmin, another serine proteinase. Plasmin is formed from the inactive precursor, plasminogen, by the activity of yet other proteolytic enzymes, urokinase, streptokinase and tissue plasminogen activator (tPA) which are also serine proteinases. These enzymes only hydrolyse plasminogen that is bound to the fibrin. Any plasmin that escapes into the general circulation is inactivated by binding to a serpin (Box 17.2). 

Three proteolytic enzymes, streptokinase, urokinase and tissue plasminogen activator, hydrolyse peptide bonds in fibrin which loosens the stracture of the clot and can results in its dispersal. This can restore flow of blood to the part of the myocardium affected by the clot. These are known as clot-busting enzymes. One or more of these enzymes is introduced into the circulation, and provided that this is done very soon after an infarct, damage to that part of the myocardium can be minimised. 

The fibrin thrombus resulting from blood clotting (see p. 290) is dissolved again by plasmin, a serine proteinase found in the blood plasma. For this purpose, the precursor plasminogen first has to be proteolyti-cally activated by enzymes from various tissues. This group includes the plasminogen activator from the kidney (urokinase) and tissue plasminogen activator (t-PA) from vascular endothelia. By contrast, the plasma protein a2-antiplasmin, which binds to active plasmin and thereby inactivates it, inhibits fibrinolysis. 

Along with the production of insulin, many other medical uses have been achieved for recombinant DNA. This includes the production of erythropoetin, a hormone used to stimulate production of red blood cells in anemic people tissue plasminogen activator, an enzyme that dissolves blood clots in heart attack victims and antihemophilic human factor VIII, used to prevent and control bleeding for hemophiliacs. These three important genetically engineered proteins were all cloned in hamster cell cultures. 

Patients who have had a heart attack or stroke are frequently treated by intravenous administration of tissue plasminogen activator (tPA) or streptokinase, enzymes that break down fibrin clots that clog blood vessels. 

Mechanism of Action A tissue plasminogen activator that activates the fibrinolytic system by directly cleaving plasminogen to generate plasmin, an enzyme that degrades the fibrin ot the thrombus. Therapeutic Effect Exerts CV-thrombolytic action. Pharmacokinetics Rapidlycleared from plasma. Eliminated primarilyby the liverand kidney. Haif-Hfe 13-16 min. 

The advent of recombinant DNA technology has allowed the isolation of genes and expression of proteins that are found in biologic tissues in exceedingly small quantities. This has permitted large-scale production of enzymes such as tissue plasminogen activator (i.e., tPA, alteplase) that cannot be extracted from tissues in quantities required for therapeutic use. Table 9.2... 

Schematic representation of the fibrinolytic system. Plasmin is the active fibrinolytic enzyme. Several clinically useful activators are shown on the left in bold. Anistreplase is a combination of streptokinase and the proactivator plasminogen. Aminocaproic acid (right) inhibits the activation of plasminogen to plasmin and is useful in some bleeding disorders. t-PA, tissue plasminogen activator.

Tissue plasminogen activator (TPA) activates plasmin, an enzyme involved in dissolving clots effective in treating heart attack patients. 

The breakdown of blood clots is illustrated in the lower part of Figure 2 5-1. Tissue plasminogen activator (t-PA) converts plasminogen to plasmin. Plasmin, also known as fibrinolysin, is an enzyme that directly breaks down the fibrin mesh, thus destroying the clot. 

For hypothermia, one major possible difficulty involves the effect of low temperature on metabolism and enzyme activity. Many pharmaceutical agents have reduced biological activity at lower temperature compared with higher temperature. The thrombolytic activity of recombinant tissue plasminogen activator (rt-PA), for example, is clearly temperature dependent, with decreased activity at lower temperature (1). Thus, the assumption that hypothermia will not have an adverse effect on other treatment agents cannot be presumed. Hypothermia is also known to reduce the activity of inflammatory and antiinfectious biological processes. This could potentially result in increased susceptibility to infection. This possibility is of particular concern because infections are a major cause of morbidity in stroke patients (2). Therefore, combination therapy with hypothermia and antiinflammatory agents could potentially worsen outcome. 

---